Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: slippage, drippage or both

July 27, 2021 7:39am

Weak trading and minor percentage moves have defined the sector recently

Pre-open indications: 1 SELLs: CLLS; 3 BUYs: IONS, CRSP, QURE and -2 Maintain SELL: BSTG, BLUE

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Dow futures are DOWN -0.20% (-71 points), S&P futures are DOWN -0.11% (-5 point) and NASDAQ futures are UP +0.05% (+8 points)

Stock futures were mixed although the Nasdaq was sputtering in early trading Tuesday,

European markets fell,

Asia-Pacific markets were mixed as China crackdowns casts its shadows while Australia and Japan gain.

Data Docket: U.S. new orders for durable goods

The Federal Reserve’s two-day policy meeting also begins Today. Investors are awaiting insights into the central bank’s monetary policy. The Federal Open Market Committee will release a statement when the meeting concludes Wednesday, followed by Chairman Jerome Powell’s news conference. <CNBC>

Henry’omics:

As record highs extend their pace, I say … BYE.

U.S. stock indexes closed Monday’s regular session at record highs to each notch five (5) day win streaks: The Dow gained +0.24%. The S&P 500 also added +0.24% and the Nasdaq closed +0.03% higher.

Monday’s evening’s recap: “first to release, uniQure NV (QURE) jumps the net income fence and then some with a 1st half/24 runway in a Q2 earnings’ release. Don’t get comfortable, there are more releases to come forth in the first few sessions in August” … https://www.regmedinvestors.com/articles/12019

The Nasdaq closed UP +3.72 points (+0.03%)
The IBB closed down -1.89% and XBI closed down -1.81%
Sector volume was LOW with 2 of the 12-upside having higher than the 3-month average volume with very LOW volume of 3 of 21-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was up +0.38 points or +2.21% at 17.58
Monday’s percentage (%) of the 12-upside were +0.30% (VSTM) to +3.84% (QURE) while the 21-downside ranges from -1.38% (MESO) to -4.68% (RGNX);

Week to date 1 negative close

Q3/21: July, 5 positive, 1 holiday and 12 negative close

Q2/21:

June: 15 positive and 8 negative closes
May: 8 positive, 12 negative closes and 1 holiday
April: 11 negative and 10 positive closes

Q1/21:

March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – Could the share price stay up if it wasn’t being “pumped”?

Biostage (BSTG) closed down -$0.06 to $1.65 with 406 shares traded after being flat, Friday and Thursday with 200 shares traded 9each session) after Wednesday’s +$0.01 with 200 shares traded, Tuesday’s flat at $1.70 with 49 shares traded and Monday’s +$0.01 to $1.71 with 307 shares traded.

Question#1: WHAT is the end game or play-book for this company, it has not done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?

Question#2: Is it “alleged market manipulation” i.e., “promotional’ tactics that highlight how this equity is traded on the over-the-counter market?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

The morning’s indications:

BUY from SELL:

Ionis Pharmaceuticals (IONS) closed down -$0.61 to $37.42 with a positive +$1.04 or +2.78% indication based on Biogen (BIIB)and IONS reporting positive topline P1b clinical study data on investigational Alzheimer's disease treatment at AAIC

CRISPR Therapeutics (CRSP) closed down -$3.05 to $119.11 after Monday’s -$2.50 to $122.27 and has a positive pre-open indication of +$0.28 or +0.23%

BUY:

uniQure NV (QURE) closed up +$1.00 and has a positive +$0.14 or +0.52% pre-market indication after a net income earnings’ release i.e., strong beat.

SELL:

Cellectis SA (CLLS) closed down -$0.58 to $13.17 and has a negative -$0.10 or -0.76% pre-market indication.

Maintaining SELL:
bluebird bio (BLUE) closed up +$0.20 to $26.18 after Monday’s down -$1.00 to $25.98 and Friday’s -$0.51 to $26.98 and has a negative -$0.18 or -0.69% pre-market indication.

The BOTTOM LINE: Volatility is still front-and-center in the sector …

Monday, the IBB closed down -1.89% and XBI closed down -1.81%
Friday, the IBB closed up +0.88% and XBI closed down -1.14%
Thursday, the IBB closed up +0.26% and XBI closed down -1.26%
Wednesday, the IBB closed up +0.46% and XBI closed up +0.92%
Tuesday, the IBB closed up +1.42% and XBI closed up +2.31%
Last Monday, the IBB closed up +0.68% and XBI closed up +0.16%

The cell and gene therapy sector is still confusing as sentiment rages and fades, volume slithers, momentum is burped and usurped as fundamentals seem ignored.

uniQure NV (QURE) released net income earnings’ release. More Q2 earnings LPS (loss-per-share) release date are soon to be divulged and not positively; yet another – Sage Therapeutics (SAGE) and Alnylam Pharmaceuticals (ALNY) release “earnings” on 8/3 followed by Vericel (VCEL), MiMedx (MDXG), AxoGen (AXGN) on 8/4, Brainstorm Cell Therapeutics (BCLI) on 8/5 and Athersys ATHX) on 8/9 – so far.

Risk is no doubt increasing as we head into the troublesome August and September months

My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.